CLCN6

Across TCGA pan-cancer cohorts, CLCN6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CLCN6 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CLCN6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLCN6 expression acts as an unfavorable survival marker.

BRCA, UCEC, and SKCM are the cancer types where CLCN6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.456	0.903	<.001	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
SKCM	DFS	Median	III,IV	0.236	0.664	.006	10	view →
THCA	DFS	Median	All	0.061	0.841	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CLCN6–BRCA (DFS)

Open the BRCA breakdown →